Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy

November 07, 2023 By The ASCO Post Staff

Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data showed this regimen continued to reduce the risk of developing invasive and distant disease recurrence well beyond the completion of treatment. The improvement at 5 years is consistent with a carryover effect and further supports the use of the CDK4/6 inhibitor abemaciclib in this population (Abstract LBA17).

Related Content